乌干达1996 - 1997年抗结核药物耐药性监测

Anti-tuberculosis drug resistance surveillance in Uganda 1996-1997.

作者信息

Bretzel G, Aziz M, Wendl-Richter U, Adatu F, Aisu T, van Wijnen A, Sticht-Groh V

机构信息

Armauer Hansen Institute/German Leprosy Relief Association, Würzburg.

出版信息

Int J Tuberc Lung Dis. 1999 Sep;3(9):810-5.

PMID:10488890

Abstract

SETTING

Drug resistance surveillance conducted by the National Tuberculosis and Leprosy Control Programme (NTLP) Uganda from 1996-1997 in collaboration with the Armauer Hansen Institute/German Leprosy Relief Association (GLRA), Germany, for the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance.

OBJECTIVE

To determine the prevalence of primary and acquired anti-tuberculosis drug resistance in Uganda.

DESIGN

The survey area covered three GLRA-supported operational NTLP zones, corresponding to 50% of the Ugandan population. A representative random sampling of individual patients was chosen as sampling procedure. Altogether 586 smear-positive TB patients (537 new cases and 49 previously treated cases) were included in the survey.

RESULTS

For primary resistance the results were as follows: isoniazid (H) 6.7%, rifampicin (R) 0.8%, ethambutol (E) 6.1%, streptomycin (S) 13.4%, thioacetazone (T) 3.2%, pyrazinamide (Z) 0%, multidrug resistance (MDR) 0.5%; for acquired resistance they were: H 37.8%, R 4.4%, S 22.2%, E 11.1%, T 20.0%, Z 0%, and MDR 4.4%.

CONCLUSION

According to these data the NTLP Uganda has been effective in preventing high levels of primary drug resistance. If it is assumed that the sampling process reflects the distribution of new patients and previously treated patients in the study areas, the amount of acquired resistance (any resistance) in the community of smear-positive patients is approximately 5%. To further monitor programme performance the NTLP will embark on a nationwide survey in 1998/1999.

摘要

背景

1996 - 1997年，乌干达国家结核病和麻风病控制项目（NTLP）与德国阿马尔·汉森研究所/德国麻风病救济协会（GLRA）合作，开展了耐药性监测，该监测是世界卫生组织/国际防痨和肺部疾病联盟（WHO/IUATLD）全球抗结核药物耐药性监测项目的一部分。

目的

确定乌干达原发性和获得性抗结核药物耐药性的流行情况。

设计

调查区域覆盖了GLRA支持的NTLP三个业务区，对应乌干达50%的人口。采用代表性随机抽样选取个体患者作为抽样程序。共有586例涂片阳性结核病患者（537例新病例和49例既往治疗病例）纳入调查。

结果

原发性耐药结果如下：异烟肼（H）6.7%，利福平（R）0.8%，乙胺丁醇（E）6.1%，链霉素（S）13.4%，硫代乙酰胺（T）3.2%，吡嗪酰胺（Z）0%，多重耐药（MDR）0.5%；获得性耐药结果如下：H 37.8%，R 4.4%，S 22.2%，E 11.1%，T 20.0%，Z 0%，MDR 4.4%。